Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: A meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Study	Country/region	No. of HCC (M/F), age (yr)	No. of controls (M/F), age (yr)	No. of DQB1 alleles studied	Type of control	HLA genotyping method
Li et al[10], 1995	Hong Kong	49 (-/-), ND	78 (-/-), ND	11	Healthy	PCR-SSP
Donaldson et al[11], 2001	Hong Kong	84 (79/5), 55	124 (-/-), ND	10	Healthy	PCR-SSOP
De Re et al[12], 2004	Italy	29 (-/-), ND	144 (-/-), ND	5	Healthy	PCR-SSP
López-Vázquez et al[13], 2004	Spain	46 (27/19), 62 ± 8	48 (19/29), 56 ± 12	10	HCV carriers	PCR-SSOP
Liu et al[14], 2007	China	78 (63/15), 58.8 ± 11.5	100 (-/-), ND	19	Healthy	PCR-SSP
El-Chennawi et al[15], 2008	Egypt	50 (45/5), 51.16 ± 6.16	50 (44/6), 48.88 ± 9.22	5	Healthy	PCR-SSP
Pan[16], 2009	China	62 (52/10), 53.58	50 (29/21), 30.12	8	Healthy	PCR-SSP

HCC: Hepatocellular carcinoma; HLA: Human leukocyte antigen; ND: Not described; PCR-SSOP: Polymerase chain reaction-sequence-specific oligonucleotides probes; PCR-SSP: Polymerase chain reaction-sequence specific primer; (-/-): No data was mentioned in the included studies.